Overview

Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

Status:
Recruiting

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

No agent is known to have efficacy in patients with incurable HNSCC that progressed with prior platin, 5-FU, cetuximab and taxane. Herein lies the unmet need to be addressed by this trial. Based on the preclinical and clinical data presented, the investigators propose that mitomycin C will have anti-tumor activity in these patients.

Phase:

Phase 2

Details

Lead Sponsor:

Washington University School of Medicine

Treatments:

Cetuximab
Mitomycin
Mitomycins
Taxane